OCV

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

Ossio is an orthopedic fixation company dedicated to enhancing the orthopedic experience for patients, healthcare providers, and payors. Established in 2014, the company focuses on developing innovative alternatives to traditional metal implants in the orthopedic fixation market, which is valued at over $10 billion. Their flagship product, OSSIOfiber, utilizes Intelligent Bone Regeneration Technology, offering a biocomposite material that is designed to support the natural healing process. This breakthrough platform allows for secure fixation while enabling the body to regenerate bone tissue, effectively replacing the implant without leaving any permanent material behind. Ossio's technology addresses the limitations of conventional bio-resorbable materials, providing the necessary mechanical strength for easy insertion and stable fixation, while promoting better healing outcomes for patients with orthopedic disorders.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Ozette Technologies focuses on digitizing biological data through machine learning to provide comprehensive insights into the human immune system. By leveraging a single-cell immune monitoring platform, the company enhances the discovery and annotation of immune cells, facilitating a deeper understanding of immune responses in both health and disease. Its AI-driven computational analysis technology supports scientists and healthcare providers in developing novel therapies and diagnostics, ultimately aiming to improve patient outcomes. Through its innovative approach, Ozette accelerates the advancement of therapeutic solutions by streamlining the analysis of immune data.

Ockam Inc. is a provider of a serverless platform designed for secure Internet-of-Things (IoT) development. Founded in 2017 and headquartered in San Francisco, California, the company offers tools that enable the interconnection of hardware with software services, facilitating secure information exchange among connected systems. Ockam's platform manages identities, cryptographic keys, and credentials for devices and services while optimizing connectivity and messaging. It simplifies the development process by eliminating the complexities of system administration, such as managing IP backlogs and setting up public APIs. The platform is open-source, secure-by-design, and built in Rust, allowing for robust end-to-end encryption, key management, and mutual authentication. Ockam connects application developers, system integrators, hardware engineers, and cloud service product managers, providing a cohesive environment for building trustworthy applications across diverse networks.

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders marked by neuronal imbalance. Established in 2015 and headquartered in Cambridge, Massachusetts, the company leverages genetic insights to create innovative treatments for neurological and psychiatric conditions. Its leading product candidates include PRAX-114, an allosteric modulator targeting GABAA receptors, currently undergoing Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, along with PRAX-222, an antisense oligonucleotide aimed at treating patients with SCN2A epilepsy, and a program focused on KCNT1-related epilepsy. The company has established collaborations and licensing agreements with various organizations to enhance its research and development efforts.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional location in Tel Aviv, Israel, SafeBreach offers a platform that enables organizations to proactively assess their security posture. The platform utilizes a comprehensive Hacker's Playbook, which includes real-world breach methods, to simulate potential attacks across various network segments, cloud environments, and endpoints. By mimicking the tactics of virtual hackers, SafeBreach helps businesses identify vulnerabilities and improve their security controls before actual breaches occur. The platform integrates seamlessly with security information and event management systems, ticketing systems, and automation vendors, allowing for enhanced incident response and remediation. Funded by notable investors, SafeBreach continues to innovate in the field of cybersecurity, providing vital insights to strengthen enterprise defenses against evolving threats.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Figure8 Inc. is a New York-based company that operates a recreational facility focused on frozen dessert-themed attractions, games, and crafts. Founded in 2016 by Manish Vora and Maryellis Bunn, Figure8 is dedicated to creating immersive experiences that foster connections and creativity. The company emphasizes the importance of imagination and aims to enhance relationships with both people and places through its offerings.

Ossio is an orthopedic fixation company dedicated to enhancing the orthopedic experience for patients, healthcare providers, and payors. Established in 2014, the company focuses on developing innovative alternatives to traditional metal implants in the orthopedic fixation market, which is valued at over $10 billion. Their flagship product, OSSIOfiber, utilizes Intelligent Bone Regeneration Technology, offering a biocomposite material that is designed to support the natural healing process. This breakthrough platform allows for secure fixation while enabling the body to regenerate bone tissue, effectively replacing the implant without leaving any permanent material behind. Ossio's technology addresses the limitations of conventional bio-resorbable materials, providing the necessary mechanical strength for easy insertion and stable fixation, while promoting better healing outcomes for patients with orthopedic disorders.

Invoice2go is a technology company dedicated to simplifying the operational processes for small business owners and freelancers globally. The platform provides a comprehensive suite of tools that enable users to create professional invoices, manage appointments, track jobs, and accept various payment methods. By offering features such as expense tracking and reporting, Invoice2go helps users maintain organization and professionalism, ultimately aiding in business growth. Founded by a small business owner with a background in trades, the company has grown to serve over 210,000 users across more than 160 countries, facilitating the sending of $24 billion in invoices annually. Its teams, located in Redwood City, California, and Sydney, Australia, consist of professionals with experience from notable companies in the tech and finance sectors.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.